Lung cancer: genes and variants
Explore variant evidence for Lung cancer across 10 analyzed proteins (PRKN, BRAF, KRAS, PIK3CA, ALK and 5 more). Linked ClinVar records include 9 pathogenic or likely pathogenic variants, 39 variants of uncertain significance and 1 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Counts refer to the selected disease label.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Lung cancer
PRKN: E3 ubiquitin-protein ligase parkin
Its parkin ubiquitin-ligase activity marks damaged mitochondrial proteins after PINK1 activation and helps eliminate dysfunctional mitochondria through mitophagy. Biallelic loss-of-function variants are a major cause of autosomal recessive juvenile or early-onset Parkinson disease.
4 ClinVar pathogenic / likely pathogenic and 7 uncertain variants in PRKN have source records linked to Lung cancer. Association strength is not clinical gene validity.
BRAF: Serine/threonine-protein kinase B-raf
It relays activated RAS signals through MEK and ERK to control proliferation, differentiation, and survival. Activating variants, especially V600E, drive melanoma and several other cancers and create sensitivity to pathway-directed therapies.
1 ClinVar pathogenic / likely pathogenic and 6 uncertain variants in BRAF have source records linked to Lung cancer. Association strength is not clinical gene validity.
KRAS: GTPase KRas
A small GTPase that acts as a molecular switch in the RAS-MAPK signaling pathway. By cycling between GDP- and GTP-bound states, it relays growth and survival signals, and activating KRAS variants are common drivers of cancer.
1 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in KRAS have source records linked to Lung cancer. Association strength is not clinical gene validity.
PIK3CA: Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform
Its p110-alpha catalytic activity generates PIP3 and activates AKT-dependent growth, survival, and metabolic signaling downstream of many receptors. Activating variants are frequent cancer drivers and, when present mosaically during development, can cause PIK3CA-related overgrowth spectrum.
1 ClinVar pathogenic / likely pathogenic and 1 uncertain variants in PIK3CA have source records linked to Lung cancer. Association strength is not clinical gene validity.
ALK: ALK tyrosine kinase receptor
Its kinase signaling influences neural development and cell growth, but constitutive activation can become strongly oncogenic. ALK fusions, activating mutations, or amplification drive anaplastic large-cell lymphoma, subsets of lung cancer, and neuroblastoma and can be targeted with ALK inhibitors.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in ALK have source records linked to Lung cancer. Association strength is not clinical gene validity.
ERBB2: Receptor tyrosine-protein kinase erbB-2
ERBB2, also called HER2, is a cell-surface receptor tyrosine kinase that works with other ERBB receptors to transmit growth signals. It helps organize signaling and cytoskeletal responses, and abnormal ERBB2 activity is a major feature of several cancers.
0 ClinVar pathogenic / likely pathogenic and 25 uncertain variants in ERBB2 have source records linked to Lung cancer. Association strength is not clinical gene validity.
CD274: Programmed cell death 1 ligand 1
By engaging PD-1, it suppresses activated T cells by engaging PD-1 and thereby limits immune-mediated tissue damage. Many cancers exploit high PD-L1 expression to evade immune attack, making the PD-1/PD-L1 axis a central target of immune-checkpoint therapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in CD274 have source records linked to Lung cancer. Association strength is not clinical gene validity.
EGFR: Epidermal growth factor receptor
A cell-surface receptor tyrosine kinase that responds to epidermal-growth-factor family ligands. Ligand binding activates phosphorylation cascades that regulate cell growth, survival, and differentiation, which is why EGFR changes are important in cancer biology.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in EGFR have source records linked to Lung cancer. Association strength is not clinical gene validity.
PDCD1: Programmed cell death protein 1
PDCD1 is an inhibitory receptor on activated T cells that binds PD-L1 and PD-L2. Its signaling helps maintain immune tolerance by restraining T-cell activation, making the protein important in autoimmunity and cancer immunotherapy.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in PDCD1 have source records linked to Lung cancer. Association strength is not clinical gene validity.
NFE2L2: Nuclear factor erythroid 2-related factor 2
It activates antioxidant, detoxification, and metabolic genes when released from KEAP1-mediated degradation. Somatic activating variants can lock cancer cells into a persistent stress-resistant state and promote therapy resistance.
1 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in NFE2L2 have source records linked to Lung cancer. Association strength is not clinical gene validity.
ClinVar pathogenic and likely pathogenic variants linked to Lung cancer
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| KRAS G12D | 12 | Pathogenic / likely pathogenic (★★) | |
| PRKN G430D | 430 | RING-type 2 | Pathogenic / likely pathogenic (★★) |
| PRKN C253Y | 253 | RING-type 1 | Pathogenic / likely pathogenic (★★) |
| PIK3CA N345K | 345 | C2 PI3K-type | Pathogenic / likely pathogenic (★★) |
| PRKN K211N | 211 | RING-type 0 | Pathogenic / likely pathogenic (★★) |
| PRKN R33Q | 33 | Ubiquitin-like | Pathogenic / likely pathogenic (★★) |
| ALK V1180L | 1180 | Protein kinase | Pathogenic / likely pathogenic |
| NFE2L2 E82D | 82 | ETGE motif | Pathogenic / likely pathogenic |
| BRAF A712D | 712 | Protein kinase | Pathogenic / likely pathogenic |
Which prediction tools work for Lung cancer
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 90 out of 100
- ESM1b (LLR): 89 out of 100
- CATVariant: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- PolyPhen-2: 83 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 82 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Same protein, different disease
- Autosomal recessive juvenile Parkinson disease 2 also has ClinVar records linked to PRKN variants; they fall mostly in different places as the Lung cancer variants (15 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung cancer variants (36 pathogenic / likely pathogenic).
- Cardio-facio-cutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung cancer variants (26 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung cancer variants (17 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung cancer variants (11 pathogenic / likely pathogenic).
- Noonan syndrome and Noonan-related syndrome also has ClinVar records linked to BRAF variants; they fall mostly in different places as the Lung cancer variants (10 pathogenic / likely pathogenic).
- RASopathy also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Lung cancer variants (23 pathogenic / likely pathogenic).
- Noonan syndrome also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Lung cancer variants (16 pathogenic / likely pathogenic).
- Cardiofaciocutaneous syndrome also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Lung cancer variants (9 pathogenic / likely pathogenic).
- Autoimmune lymphoproliferative syndrome also has ClinVar records linked to KRAS variants; they fall partly in the same places as the Lung cancer variants (5 pathogenic / likely pathogenic).
- Non-small cell lung carcinoma also has ClinVar records linked to KRAS variants; they fall mostly in different places as the Lung cancer variants (5 pathogenic / likely pathogenic).
- PIK3CA related overgrowth syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Lung cancer variants (30 pathogenic / likely pathogenic).
- Cowden syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Lung cancer variants (23 pathogenic / likely pathogenic).
- Megalencephaly-capillary malformation-polymicrogyria syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Lung cancer variants (22 pathogenic / likely pathogenic).
- Ovarian neoplasm also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Lung cancer variants (5 pathogenic / likely pathogenic).
- PIK3CA constitutional syndrome also has ClinVar records linked to PIK3CA variants; they fall mostly in different places as the Lung cancer variants (4 pathogenic / likely pathogenic).
- Immunodeficiency, developmental delay, and hypohomocysteinemia also has ClinVar records linked to NFE2L2 variants; they fall partly in the same places as the Lung cancer variants (3 pathogenic / likely pathogenic).
Diseases related to Lung cancer
- Non-small cell lung carcinoma, also linked to ALK, BRAF, CD274, EGFR and 4 more
- Colorectal cancer, also linked to BRAF, EGFR, ERBB2, KRAS and 2 more
- Head and neck squamous cell carcinoma, also linked to CD274, EGFR, NFE2L2, PDCD1 and 1 more
- Ovarian cancer, also linked to ALK, ERBB2, PIK3CA and PRKN
- Gastric cancer, also linked to ERBB2, KRAS, PDCD1 and PIK3CA
- Urinary bladder cancer, also linked to EGFR, ERBB2, KRAS and PIK3CA
- Lung adenocarcinoma, also linked to BRAF, EGFR, ERBB2 and KRAS
- Hepatocellular carcinoma, also linked to BRAF, CD274, NFE2L2 and PIK3CA
- Noonan syndrome, also linked to BRAF, KRAS and PIK3CA
- Ovarian neoplasm, also linked to ERBB2, PIK3CA and PRKN
- Gastric neoplasm, also linked to ERBB2, PDCD1 and PIK3CA
- RASopathy, also linked to BRAF and KRAS
Frequently asked questions
Which genes have records linked to Lung cancer?
This view contains 10 analyzed proteins: PRKN, BRAF, KRAS, PIK3CA, ALK and 5 more. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 9 pathogenic or likely pathogenic variants, 39 variants of uncertain significance and 1 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 0 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 60 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center